The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Open accessAbstract
Lung cancers undergo dynamic genetic and histological changes upon developing resistance to EGFR inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The “gatekeeper” T790M mutation is a well-characterized mechanism of acquired resistance to first- and second-generation TKIs, which has been reported to occur in >60% of cases.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite the efficacy of EGFR TKIs in the first-line treatment of EGFRm+ NSCLC, acquired resistance to therapy occurs in the majority of patients.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common mechanism of resistance to first-generation EGFR TKIs is the development of the gatekeeper T790M mutation, which occurs in approximately 50–70% of patients.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In two patients with NSCLC for whom we were not able to identify a genomic resistance mechanism, we observed histologic transformation from adenocarcinoma to squamous-cell carcinoma, which suggests that nongenetic mechanisms of resistance to KRASG12C inhibition may occur, similar to those observed with other targeted therapies in lung cancer.24-26”
From Acquired Resistance to KRAS G12C Inhibition in Cancer (2021) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“the histologic transformation of lung adenocarcinoma subtype to small cell carcinoma subtype, which accounts for 5–15% of EGFR-mutant lung cancer patients with acquired resistance to EGFR TKIs [12,17].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [12]
In the citing paper
“after using first-generation EGFR TKIs for approximately 9–14 months, almost all tumors progressed again.111”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [111]
In the citing paper
“the EGFR T790M gatekeeper mutation, is a leading cause of resistance to first- and second-generation EGFR inhibitors [11,12].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [12]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [12]
In the citing paper
“Similar phenomenon occurs in other targeted therapies for lung cancer [94, 140, 141].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [141]
In the citing paper
“Genomic sequencing of EGFR from both the baseline and repeated biopsy samples shows that a transformed SCLC tumour sample retained the original EGFR-activating mutation, suggesting that these were not de novo clones, but rather a transformed phenotype of pre-existing cancer cells.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“Repeated bioptic sampling from patients with EGFR-mutant NSCLCs have shown a rare but consistent observation of histological transformation from adenocarcinoma to small cell lung cancer (SCLC).34”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“However, patients with adenocarcinoma-SCLC transformation presented mixed responses to EGFR inhibitors, despite the persistency of the activating mutation, probably due to the loss of EGFR expression at the protein level.34”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“Activation of other cell receptors such as FGFR1,2,351 or of cell signalling pathways such as BRAF (Val600Glu, Gly469Ala) mutation (1%)52 and PIK3CA mutation (5%)34, that play a key role in promoting the proliferation, survival, drug resistance of cancer cells, have been described.”
From Mechanisms of resistance to EGFR-targeted drugs: lung cancer (2016) · cites this paper as [34]
In the citing paper
“A secondary epidermal growth factor receptor (EGFR) mutation, T790M, is the most common resistance mechanism in EGFR mutant adenocarcinomas that have progressed on erlotinib.”
In the citing paper
“These data are further supported by the clinical observations that EGFR mutant SCLCs are highly sensitive to SCLC chemotherapy regimens7.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“As reported previously, all of the resistant SCLC cancers harboured the original activating EGFR mutation7.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“Importantly, the tumours that transformed to SCLC harboured the original activating EGFR mutation, suggesting direct evolution from the initial cancer, rather than a distinct, second primary cancer.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“Both SCLC transformed samples harboured an activating mutation in PIK3CA, which we previously observed in SCLC transformed cases7”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“However, repeat biopsy studies have consistently suggested that the SCLC transformed cancers represent an evolution from the initial adenocarcinomas rather than a second coincident cancer, because the activating driver EGFR mutations are identical to the original adenocarcinomas in all cases.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“One unexpected finding from these studies was the discovery that 5–15% of patient tumours undergo transformation to SCLC histology upon acquisition of resistance.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“However, from a clinical perspective, we feel that it is unlikely that these SCLCs were present from the onset of the disease in a majority of these cases because when the SCLC surfaces in the clinic, it progresses quite rapidly (like classical SCLC)7.”
From RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer (2015) · cites this paper as [7]
In the citing paper
“is most commonly due to the EGFR T790M mutation, present in approximately 50 to 60% of resistant cases.5,6”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [5]
In the citing paper
“Epithelial‐mesenchymal transition (EMT) has also been indicated as one mechanism of resistance to EGFR-TKIs[10].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [10]
In the citing paper
“At the time of progression, about 60% of patients (regardless of race or ethnic background) are found to have a p.Thr790Met point mutation (T790M) in the gene encoding EGFR.13–16”
From Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2017) · cites this paper as [15]
In the citing paper
“Resistance to conventional EGFR-TKIs develops after a median of 10 to 12 months and is most commonly mediated by an acquired mutation, T790M1-5.”
From Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer (2016) · cites this paper as [4]
In the citing paper
“with the EGFR T790M somatic mutation being the most frequent alteration detected in approximately half of progressing tumors.[14][15][16]”
In the citing paper
“Other resistance mechanisms involve bypass pathways such as MET proto-oncogene, receptor tyrosine kinase gene (MET) amplification (5%-30% depending on thresholds), erb-b2 receptor tyrosine kinase 2 (HER2) amplification (12%), phosphatidylinositol-4,5bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) mutation (5%), and B-Raf proto-oncogene, serine/threonine kinase gene (BRAF) mutation (1%)”
In the citing paper
“the most common finding in EGFR-mutated tumours relapsing after first-/secondgeneration EGFR TKI therapy [19].”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [19]
In the citing paper
“each initial EGFR sensitizing mutation is an early “truncal” event in the pathogenesis of lung adenocarcinoma, and previous studies have not detected significant heterogeneity across multiple biopsies (5,37).”
From Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses (2016) · cites this paper as [5]
In the citing paper
“Genomic heterogeneity within tumors and across metastatic tumor sites in the same patient is the major cause of treatment failure and emergence of therapy resistance (19).”
From Radiomics: Images Are More than Pictures, They Are Data (2016) · cites this paper as [19]
In the citing paper
“Accordingly, PIK3CA mutations have been identified in biopsies of EGFR mutant cancers with acquired resistance to EGFR inhibitors (Sequist et al., 2011).”
From ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics (2014) · cites this paper as Sequist et al., 2011
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
Self-citationEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“They have identified several resistance mechanisms, two of which—EGFR mutation T790M (6, 7) andMET amplification (8, 9)—have been validated in the clinic.”
Background
Cited by
Sorted by citations
Items 301–400 of 1,021
Lu, X., Yu, L., Zhang, Z., Ren, X., Smaill, J. B., & Ding, K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21488 · Cited by 173
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
New Approaches to SCLC Therapy: From the Laboratory to the Clinic
Poirier, J. T., George, J., Owonikoko, T. K., Berns, A. J. M., Brambilla, E. M., Byers, L. A., Carbone, D. P., Chen, H. J., Christensen, C. L., Dive, C., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.016 · Cited by 176
Crizotinib in Patients With MET-Amplified NSCLC
Camidge, D. R., Otterson, G. A., Clark, J. W., Ou, S. I., Weiss, J. M., Ades, S., Shapiro, G. I., Socinski, M. A., Murphy, D. A., Conte, U., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.02.010 · Cited by 177
Emerging strategies to overcome resistance to third-generation EGFR inhibitors
Shi, K., Wang, G., Pei, J., Zhang, J., Wang, J., Ouyang, L., Wang, Y., & Li, W. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01311-6 · Cited by 174
Yang, J., Zhang, X., Su, J., Xu, C., Zhou, Q. H., Tian, H.-X., Xie, Z., Chen, H.-J., Huang, Y.-S., Jiang, B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0699 · Cited by 171
New Perspectives, Opportunities, and Challenges in Exploring the Human Protein Kinome
Wilson, L., Linley, A. J., Hammond, D. E., Hood, F. E., Coulson, J. M., MacEwan, D. J., Ross, S. J., Slupsky, J. R., Smith, P. D., Eyers, P. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2291 · Cited by 178
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
Du, X., Yang, B., An, Q., Assaraf, Y. G., Cao, X., & Xia, J. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100103 · Cited by 171
Patel, H., Pawara, R., Ansari, A., & Surana, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.05.027 · Cited by 170
Converting Cancer Therapies into Cures: Lessons from Infectious Diseases
Glickman, M. S., & Sawyers, C. L. (2012) · Cell · doi:10.1016/j.cell.2012.02.015 · Cited by 171
Non-canonical functions of the RB protein in cancer
Dick, F. A., Goodrich, D. W., Sage, J., & Dyson, N. J. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0008-5 · Cited by 175
Zhao, Y., Liu, J., Cai, X., Pan, Z., Liu, J., Yin, W., Chen, H., Xie, Z., Liang, H., Wang, W., et al. (2019) · BMJ · doi:10.1136/bmj.l5460 · Cited by 170
Möhrmann, L., Huang, H. J., Hong, D. S., Tsimberidou, A. M., Fu, S., Piha-Paul, S. A., Subbiah, V., Karp, D. D., Naing, A., Krug, A., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2007 · Cited by 168
Remón, J., Caramella, C., Jovelet, C., Lacroix, L., Lawson, A. R. J., Smalley, S., Howarth, K., Gale, D. G., Green, E., Plagnol, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx017 · Cited by 167
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer
Han, M., Li, F., Zhang, Y., Dai, P., He, J., Li, Y., Zhu, Y., Zheng, J., Huang, H., Bai, F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.011 · Cited by 166
Chen, Z.-Y., Zhong, W.-Z., Zhang, X.-C., Su, J., Yang, X.-N., Chen, Z.-H., Yang, J.-J., Zhou, Q., Yan, H.-H., An, S.-J., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0385 · Cited by 165
Shimamura, T., Perera, S. A., Foley, K. P., Sang, J., Rodig, S. J., Inoue, T., Chen, L., Li, D., Carretero, J., Li, Y.-C., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2967 · Cited by 167
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy
Anwar, S., Shamsi, A., Mohammad, T., Islam, A., & Hassan, M. I. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188568 · Cited by 168
Tanaka, K., Yu, H. A., Yang, S., Han, S., Selçuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A. F., Sinha, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.07.006 · Cited by 169
Mechanisms of Acquired Resistance to Targeted Cancer Therapies
Lackner, M. R., Wilson, T. R., & Settleman, J. (2012) · Future Oncology · doi:10.2217/fon.12.86 · Cited by 167
Zhang, Z., Zhou, C., Li, X., Barnes, S. D., Deng, S., Hoover, E., Chen, C.-C., Lee, Y. S., Zhang, Y., Wang, C., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.001 · Cited by 167
Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer
Cejas, P., Xie, Y., Font‐Tello, A., Lim, K., Syamala, S., Qiu, X., Tewari, A. K., Shah, N., Nguyen, H. M., Patel, R. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26042-z · Cited by 166
Kitai, H., Ebi, H., Tomida, S., Floros, K. V., Kotani, H., Adachi, Y., Oizumi, S., Nishimura, M., Faber, A. C., & Yano, S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1377 · Cited by 162
Challenges in molecular testing in non-small-cell lung cancer patients with advanced disease
Hiley, C. T., Quesne, J. P. C. L., Santis, G., Sharpe, R., de Castro, D. G., Middleton, G., & Swanton, C. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31340-x · Cited by 167
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale
Salgia, R. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0472 · Cited by 162
Therapy-induced APOBEC3A drives evolution of persistent cancer cells
Isozaki, H., Sakhtemani, R., Abbasi, A., Nikpour, N., Stanzione, M., Oh, S., Langenbucher, A., Monroe, S., Su, W., Cabanos, H. F., et al. (2023) · Nature · doi:10.1038/s41586-023-06303-1 · Cited by 168
Self-citationGlaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 169
Sholl, L. M., Weremowicz, S., Gray, S. W., Wong, K., Chirieac, L. R., Lindeman, N. I., & Hornick, J. L. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31827db604 · Cited by 161
Molecular histology of lung cancer: From targets to treatments
Wood, S. L., Pernemalm, M., Crosbie, P. A. J., & Whetton, A. D. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.02.008 · Cited by 163
Combating subclonal evolution of resistant cancer phenotypes
Brady, S. W., McQuerry, J. A., Qiao, Y., Piccolo, S., Shrestha, G., Jenkins, D. F., Layer, R. M., Pedersen, B. S., Miller, R. H., Esch, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01174-3 · Cited by 163
A Brief Report of Transformation From NSCLC to SCLC: Molecular and Therapeutic Characteristics
Ferrer, L., Levra, M. G., Brevet, M., Antoine, M., Mazières, J., Rossi, G., Chiari, R., Westeel, V., Poudenx, M., Letreut, J., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2028 · Cited by 161
Epithelial-mesenchymal transition and inflammation at the site of the primary tumor
Dominguez, C. L., David, J. M., & Palena, C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.002 · Cited by 163
Qin, K., Hou, H., Yu, L., & Zhang, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-06805-5 · Cited by 161
Li, R., Hu, Z., Sun, S., Chen, Z. G., Owonikoko, T. K., Sica, G., Ramalingam, S. S., Curran, W. J., Khuri, F. R., & Deng, X. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0095 · Cited by 159
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Cortot, A. B., & Jänne, P. A. (2014) · European Respiratory Review · doi:10.1183/09059180.00004614 · Cited by 158
Alectinib Shows Potent Antitumor Activity against RET -Rearranged Non–Small Cell Lung Cancer
Kodama, T., Tsukaguchi, T., Satoh, Y., Yoshida, M., Watanabe, Y., Kondoh, O., & Sakamoto, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0274 · Cited by 158
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Baca, S. C., Takeda, D. Y., Seo, J.-H., Hwang, J. H., Ku, S., Arafeh, R., Arnoff, T. E., Agarwal, S., Bell, C. A., O’Connor, E. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22139-7 · Cited by 163
Shea, M., Costa, D. B., & Rangachari, D. (2015) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465815617871 · Cited by 158
Deng, S., Wang, C., Wang, Y., Xu, Y., Li, X., Johnson, N. A., Mukherji, A., Lo, U., Xu, L., Gonzalez, J., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00431-9 · Cited by 163
EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
Nakagawa, T., Takeuchi, S., Yamada, T., Ebi, H., Sano, T., Nanjo, S., Ishikawa, D., Sato, M., Hasegawa, Y., Sekido, Y., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3479 · Cited by 158
Sorber, L., Zwaenepoel, K., Deschoolmeester, V., Schil, P. E. V., van Meerbeeck, J. P., Lardon, F., Rolfo, C. D., & Pauwels, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.04.026 · Cited by 159
Johnson, M. L., Garassino, M. C., Mok, T. S. K., & Mitsudomi, T. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.011 · Cited by 159
Peters, S., Zimmermann, S., & Adjei, A. A. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.010 · Cited by 155
Accessing Genetic Information with Liquid Biopsies
Cai, X., Jankú, F., Zhan, Q., & Fan, J. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.06.001 · Cited by 157
Tanizaki, J., Okamoto, I., Okabe, T., Sakai, K., Tanaka, K., Hayashi, H., Kaneda, H., Takezawa, K., Kuwata, K., Yamaguchi, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0392 · Cited by 155
Inactivation of Capicua drives cancer metastasis
Okimoto, R. A., Breitenbuecher, F., Olivas, V. R., Wu, W., Gini, B., Hofree, M., Asthana, S., Hrustanovic, G., Flanagan, J., Tulpule, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3728 · Cited by 159
Ricordel, C., Friboulet, L., Facchinetti, F., & Soria, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx705 · Cited by 156
Soucheray, M., Capelletti, M., Pulido, I., Kuang, Y., Paweletz, C. P., Becker, J. H., Kikuchi, E., Xu, C., Patel, T. B., Al‐Shahrour, F., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0377 · Cited by 157
Cancer Genes in Lung Cancer: Racial Disparities: Are There Any?
El-Telbany, A., & Ma, P. C. (2012) · Genes & Cancer · doi:10.1177/1947601912465177 · Cited by 156
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 159
Pathology and Classification of SCLC
Raso, M. G., Bota‐Rabassedas, N., & Wistuba, I. I. (2021) · Cancers · doi:10.3390/cancers13040820 · Cited by 159
Seipin: from human disease to molecular mechanism
Cartwright, B. R., & Goodman, J. M. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r023754 · Cited by 160
Uncommon EGFR mutations in advanced non-small cell lung cancer
O'Kane, G. M., Bradbury, P. A., Feld, R. D., Leighl, N. B., Liu, G., Pisters, K.-M., Kamel‐Reid, S., Tsao, M., & Shepherd, F. A. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.04.016 · Cited by 153
Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156
Takeda, M., & Nakagawa, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20010146 · Cited by 154
Sivakumar, S., Moore, J. A., Montesion, M., Sharaf, R., Lin, D. I., Colón, C. I., Fleischmann, Z., Ebot, E. M., Newberg, J. Y., Mills, J. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0620 · Cited by 154
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Wilson, C., Ye, X., Pham, T., Lin, E., Chan, S., McNamara, E., Neve, R. M., Belmont, L., Koeppen, H., Yauch, R. L., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1009 · Cited by 150
Hata, A., Katakami, N., Yoshioka, H., Kaji, R., Masago, K., Fujita, S., Imai, Y., Nishiyama, A., Ishida, T., Nishimura, Y., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000647 · Cited by 150
Ichihara, E., Westover, D., Meador, C. B., Yan, Y., Bauer, J. A., Lu, P., Ye, F., Kulick, A., de Stanchina, E., McEwen, R., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2300 · Cited by 150
EGFR Exon 19 Insertions: A New Family of Sensitizing EGFR Mutations in Lung Adenocarcinoma
He, M., Capelletti, M., Nafa, K., Yun, C.-H., Arcila, M. E., Miller, V. A., Ginsberg, M. S., Zhao, B., Kris, M. G., Eck, M. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2361 · Cited by 149
Ou, S.-H. I., Agarwal, N., & Ali, S. M. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.015 · Cited by 149
Personalized therapy for lung cancer: striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 154
Dago, A. E., Stepansky, A., Carlsson, A., Luttgen, M. S., Kendall, J., Baslan, T., Kolatkar, A. R., Wigler, M. H., Bethel, K. J., Gross, M. E., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101777 · Cited by 153
Derks, J. L., Leblay, N., Lantuéjoul, S., Dingemans, A. C., Speel, E. M., & Fernandez‐Cuesta, L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.02.002 · Cited by 148
Overcoming implementation challenges of personalized cancer therapy
Meric‐Bernstam, F., & Mills, G. B. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.127 · Cited by 150
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition
WILSON, C. A., Nicholes, K., Bustos, D. J., Lin, E., Song, Q., Stéphan, J.-P., Kirkpatrick, D. S., & Settleman, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2397 · Cited by 149
Schrock, A. B., Zhu, V. W., Hsieh, W.-S., Madison, R. W., Creelan, B., Silberberg, J., Costin, D., Bharne, A., Bonta, I. R., Bosemani, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.027 · Cited by 146
Xiang, Y., Liu, X., Wang, Y., Zheng, D., Meng, Q., Jiang, L., Yang, S., Zhang, S., Zhang, X., Liu, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1366260 · Cited by 152
Kwon, M.-C., & Berns, A. J. M. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.02.010 · Cited by 150
Ahn, M., Han, J., Lee, K. H., Kim, S.-W., Kim, D., Lee, Y., Cho, E. K., Kim, J.-H., Lee, G., Lee, J.-S., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30504-2 · Cited by 145
Allo-network drugs: harnessing allostery in cellular networks
Nussinov, R., Tsai, C., & Csermely, P. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.08.004 · Cited by 144
Yi, Y., Zeng, S., Wang, Z., Wu, M., Ma, Y., Ye, X., Zhang, B., & Liu, H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.12.021 · Cited by 145
The Landscape of Atypical and Eukaryotic Protein Kinases
Kanev, G. K., de Graaf, C., de Esch, I. J. P., Leurs, R., Würdinger, T., Westerman, B. A., & Kooistra, A. J. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.09.002 · Cited by 143
Fu, Y., Zhang, Y., Lei, Z., Liu, T., Cai, T., Wang, A., Du, W., Zeng, Y., Zhu, J., Liu, Z., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01009-7 · Cited by 145
Lee, K. H. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.001 · Cited by 142
Molecular targeted therapy in the treatment of advanced stage non‐small cell lung cancer ( NSCLC )
Kumarakulasinghe, N. B., van Zanwijk, N., & Soo, R. A. (2015) · Respirology · doi:10.1111/resp.12490 · Cited by 145
Suda, K., Mizuuchi, H., Maehara, Y., & Mitsudomi, T. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9391-7 · Cited by 143
Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes
Varghese, A. M., Zakowski, M. F., Yu, H. A., Won, H. H., Riely, G. J., Krug, L. M., Kris, M. G., Rekhtman, N., Ladanyi, M., Wang, L., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000142 · Cited by 141
Tumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 144
Akhavan, D., Pourzia, A. L., Nourian, A. A., Williams, K. J., Nathanson, D. A., Babić, I., Villa, G. R., Tanaka, K., Nael, A., Yang, H., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0502 · Cited by 143
Wang, J., Wang, B., Chu, H., & Yao, Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s106399 · Cited by 143
Targeting PI3K Signaling in Combination Cancer Therapy
Tostivint, E. P., Thibault, B., & Guillermet‐Guibert, J. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.04.002 · Cited by 141
Using tumour phylogenetics to identify the roots of metastasis in humans
Naxerova, K., & Jain, R. K. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.238 · Cited by 144
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 145
Crona, D. J., & Whang, Y. E. (2017) · Cancers · doi:10.3390/cancers9060067 · Cited by 143
Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer
Sen, T., Takahashi, N., Chakraborty, S., Takebe, N., Nassar, A. H., Karim, N. A., Puri, S., & Naqash, A. R. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00914-x · Cited by 143
c-Met as a Target for Personalized Therapy
Garajová, I., Giovannetti, E., Biasco, G., & Peters, G. J. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30534 · Cited by 141
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 138
Self-citationDickinson, P. A., Cantarini, M., Collier, J., Frewer, P., Martin, S. W., Pickup, K., & Ballard, P. G. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.069203 · Cited by 139
Hong, S., Chen, N., Fang, W., Zhan, J., Liu, Q., Kang, S., He, X., Liu, L., Zhou, T., Huang, J., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1094598 · Cited by 138
Rubin, M. A., Bristow, R. G., Thienger, P., Dive, C., & Imielinski, M. B. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.10.033 · Cited by 140
Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 137
Sun, Y., Daemen, A., Hatzivassiliou, G., Arnott, D. P., WILSON, C. A., Zhuang, G., Gao, M., Liu, P. J., Boudreau, A., Johnson, L., et al. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-20 · Cited by 134
Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib
Fujita, S., Masago, K., Katakami, N., & Yatabe, Y. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.105 · Cited by 133
Corcoran, R. B., Settleman, J. E., & Engelman, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.262 · Cited by 133
Self-citationNovel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 133
Targeting the KRAS Pathway in Non-Small Cell Lung Cancer
Tomasini, P., Walia, P., Labbé, C., Jao, K., & Leighl, N. B. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0084 · Cited by 135
Wen, S., Dai, L., Wang, L., Wang, W., Wu, D., Wang, K., He, Z., Wang, A., Chen, H., Zhang, P., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0572 · Cited by 131
PTEN Is a Potent Suppressor of Small Cell Lung Cancer
Cui, M., Augert, A., Rongione, M. A., Conkrite, K. L., Parazzoli, S. D., Nikitin, A. Y., Ingolia, N. T., & MacPherson, D. P. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0554 · Cited by 131
Goldberg, S. B., Oxnard, G. R., Digumarthy, S., Muzikansky, A., Jackman, D. M., Lennes, I. T., & Sequist, L. V. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0168 · Cited by 130
Self-citation
Metadata
- Authors
- Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., Akhavanfard, S., Heist, R. S., Temel, J., Christensen, J. G., Wain, J. C., Lynch, T. J., Vernovsky, K., Mark, E. J., Lanuti, M., Iafrate, A. J., Mino-Kenudson, M., & Engelman, J. A.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Yale Cancer Center (US)
- Pfizer (United States) (US)
- Corresponding author
- Sequist, Lecia V.
- Waltman, Belinda A.
- Dias-Santagata, Dora
- Engelman, Jeffrey A.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2011-03-23
- Volume
- 3
- Issue
- 75
- Pages
- 75ra26-75ra26
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC3132801
- OpenAlex
- W1980497534
- Cited by
- 3,499
- References
- 64
- Citations by year
- 2026: 95 · 2025: 141 · 2024: 160 · 2023: 178 · 2022: 249 · 2021: 265 · 2020: 281 · 2019: 259 · 2018: 298 · 2017: 331 · 2016: 279 · 2015: 270 · 2014: 232 · 2013: 253 · 2012: 154
- FWCI
- 188.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA127003, U01CA141457, K08 GRANT CA120060-01, R01CA140594, R21CA156000, P50CA090578, P20CA090578, K08CA120060, R01CA137008)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR inhibitors, drug resistance, non-small cell lung cancer, EGFR mutation, T790M mutation, MET amplification, EGFR amplification, PIK3CA mutation, epithelial-mesenchymal transition, small cell lung cancer transformation, histological evolution, serial biopsies, tyrosine kinase inhibitors
- MeSH terms
- Erlotinib Hydrochloride, Gefitinib, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Biopsy, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Phenotype, Quinazolines, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
